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SummAry – vitamin B12 is one of the essential vitamins that affect various systems in the 
body, including the central nervous system. vitamin B12 plays an important part in the metabolism 
of the nervous system, although its exact role under pathological conditions is not fully understood. 
The purpose of this study was to emphasize the importance of early diagnosis of vitamin B12 defi-
ciency in the light of the characteristics of the patients enrolled. This retrospective, clinical study in-
cluded 38 children with neurological symptoms of vitamin B12 deficiency. records of 38 patients 
referred to a single center of the university hospital outpatient child neurology clinic due to neuro-
logical symptoms of vitamin B12 deficiency between february 2012 and december 2013 were evalu-
ated retrospectively. Patients aged 0-18 years with symptoms including syncope, dizziness, convulsion, 
hypotonia, developmental retardation, tremor, ataxia, tingling sensations and paresthesia, blurring of 
vision, fatigue and concentration difficulty caused by vitamin B12 deficiency were included in the 
study. Patient neurological findings included syncope (n=6), dizziness (n=4), hypotonia (n=9), inabil-
ity to sit or walk without support, or gait ataxia (n=2), convulsion (n=4), hand tremor (n=1), tingling 
sensations and paresthesia (n=3), vision blurring (n=1), fatigue and concentration difficulty (n=8). All 
patients with neurological symptoms of vitamin B12 deficiency recovered within one month after vi-
tamin B12 supplementation. in conclusion, clinical characteristics of vitamin B12 deficiency are broad 
and nonspecific and may not be associated with anemia and increased mean corpuscular volume. Since 
different clinical characteristics can be seen without anemia, awareness and cautious approach are es-
sential in order to avoid severe clinical disease, especially in children from underdeveloped countries.
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Introduction
Nutrition support is very important in all age 
groups, especially in children and the elderly1,2. Nutri-
tional B12 deficiency is rare in children with nonspe-
cific symptoms, including failure to thrive, vomiting, 
anorexia and neurological changes with or without 
hematologic disturbances. Symptoms cover a broad 
spectrum, including weakness, tiredness, lightheaded-
ness, rapid heartbeat and breathing, pale skin, soreness, 
easy bruising and bleeding, sore tongue, gastric upset, 
weight loss, diarrhea or constipation, lack of motiva-
tion and energy, muscle weakness and tingling in the 
extremities. Other neurological findings include al-
tered sensation, paresthesia in the extremities, gait 
ataxia, poor vision, dizziness, loss of taste or smell, uri-
nary or fecal incontinence, loss of cutaneous sensation, 
impaired sense of vibration, proprioception, psychiat-
ric manifestation, memory impairment, personality 
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changes, convulsions, hypotonia, developmental delay, 
orthostatic hypotension, postural orthostatic tachycar-
dia, poor activity and developmental delay. While it is 
common during infancy and adolescence in develop-
ing and underdeveloped countries, a high level of 
awareness is required in order to prevent permanent 
neurological damage from B12 deficiency, especially in 
children with mild symptoms1. Adenosylcobalamin 
and methylcobalamin, two forms of vitamin B12, are 
co-factors in two enzymatic reactions, either or both of 
which may impact myelin formation. Plasma homo-
cysteine increases in vitamin B12 deficiency3,4. An in-
creased level of homocysteine is related to a number of 
neurodegenerative diseases associated with neurotox-
icity and overstimulation of N-methyl-d aspartate 
receptors3-8. in case of B12 deficiency, the levels of the 
homocysteine precursor are affected because a de-
creased S-adenosylmethionine:S-adenosylhomocyste-
ine (SAm:SAH) ratio affects dNA synthesis and cell 
recycling, since folate cannot be recycled in the ab-
sence of cobalamin3-9.
The objective of this study was to determine neuro-
logical presentations and characteristics of children 
with B12 deficiency. Since methylation reactions are 
very important in many parts of the nervous system, 
cobalamin deficiency leads to a wide range of neuro-
logical presentations.
Patients and Methods
This retrospective study involved children aged 
0-18 referred to the university hospital outpatient 
child neurology clinic in turkey due to neurological 
symptoms during the 2012-2013 period. The study 
group consisted of 38 patients (20 male and 18 fe-
male), age range from 9 months to 17 years. Patients 
were classified according to their neurological signs 
and symptoms. Symptoms on admission are shown in 
table 1. None of the patients had sufficient animal 
product foodstuffs in their diet. diagnosis of B12 de-
ficiency was based on serum B12 concentrations below 
200 pg/ml. data concerning sex, age and symptoms 
of the disease, neurological examination, laboratory in-
vestigations and magnetic resonance imaging (mri), 
electroencephalography (eeg) and electromyelogra-
phy (emg) findings were collected. laboratory inves-
tigations included vitamin B12, folic acid levels, whole 
blood count, hemoglobin and hematocrit, and mean 
corpuscular volume (mCv). Patients with neurologi-
cal symptoms, serum B12 level lower than 200 pg/ml, 
and with normal folic acid levels were included in the 
study. None of the patients was on medication during 
the study, and none had symptoms of any parasitic or 
duodenal ulcer disease. ethical approval for the study 
was obtained from the local ethics committee.
treatment regimen involved B12 supplementation 
with bolus injection of 1000 mcg/ml B12 (in the 
form of cyanocobalamin) intramuscularly and repeat-
ed every week for four weeks.
Statistical analysis
data analysis was performed using the SPSS (Sta-
tistical Package for Social Sciences) version 20 data 
analysis package. One-way ANOvA was used when 
differences between the groups were evaluated because 
the variables showed normal distribution. The paired-t 
test was used because the variance between the two 
dependent variables was analyzed from normal distri-
bution. Wilcoxon test was used because the variance 
between the two dependent variables was not different 
from normal distribution. Kruskal Wallis-H test was 
used to analyze the variables between the groups, 
which did not show normal distribution. When Krus-
kal Wallis-H test yielded significant differences, the 
groups that differed were identified with the post-hoc 
multiple comparison test. When one-way ANOvA 
yielded significant differences, tukey HSd was used 
when the variances in the groups were homogeneous, 
while tamhane’s analysis was used when the variances 
were not homogeneous. The level of statistically sig-
nificant difference was set at p<0.05.
Results
Patient neurological findings included syncope 
(n=6), dizziness (n=4), hypotonia (n=9), inability to sit 
or walk without support, or gait ataxia (n=2), convul-
sion (n=4), hand tremor (n=1), tingling sensations and 
paresthesia (n=3), vision blurring (n=1), fatigue and 
concentration difficulty (n=8). Patients were divided 
into four groups by combining these findings together. 
group 1 consisted of patients with syncope and dizzi-
ness (n=10); group 2 of patients with hypotonia find-
ings (n=9); group 3 of patients with tingling sensations 
and paresthesia, fatigue, difficulty in concentrating and 
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1 m 12 Syncope 13.1 159 N interictal eeg: N
2 m 10 Syncope 13.9 168 N interictal eeg: N
3 f 11 Syncope 13.9 137 N interictal eeg: N
4 f 13 Syncope 12.4 130 N interictal eeg: N
5 f 17 Syncope 9.8 154 N interictal eeg: N
6 f 12 Syncope 12.8 126 N interictal eeg: N
7 m 14 dizziness 15.3 144 N
8 f 14 dizziness 12.1 125 N
9 f 15 dizziness 14.3 109 N
10 m 7 dizziness 12.2 147 N
11 m 24 months Hypotonia, unable to walk 11.0 143 N
12 m 10 months Hypotonia, unable to sit without support 11.5 40 N
13 m 9 months Hypotonia, unable to sit without support 11.1 172 N
14 m 10 months Hypotonia, unable to sit without support 11.1 160 N
15 m 20 months Hypotonia, unable to walk 11.3 136 NA
16 m 22 months Hypotonia, unable to walk 12.5 188 N
17 f 22 months Hypotonia, unable to walk 11.5 132 N
18 f 11 months Hypotonia, unable to sit without support 11.0 154 NA
19 m 24 months Hypotonia, unable to walk 12.0 135 N
20 m 5 gait ataxia 12.5 157 N
21 m 5 gait ataxia 11.2 196 NA
22 m 12 Convulsion/focal 12.9 120 N interictal eeg: N
23 f 3 Convulsion/generalized 11.0 143 NA interictal eeg: N
24 f 10 months Convulsion (infantile spasm) 13.3 136 N eeg: hypsarrhymia
25 m 6 Convulsion/focal 12.2 167 N interictal eeg: N
26 m 15 tremor 15.5 135 N





28 f 17 tingling sensation, paresthesia in upper distal extremities 12.3 114 NA emg: N
29 m 8 tingling sensation, paresthesia in upper distal extremities 13.6 135 NA emg: N
30 m 5 vision blurring 13.4 146 N
veP: amplitudes 
lower than normal 
on the right side
31 f 17 fatigue, difficulty in concentrating, headache 13.6 92 N
32 m 8 fatigue, difficulty in concentrating, headache 14.1 98 N
33 f 14 fatigue, difficulty in concentrating, headache 10.9 161 N
34 m 17 fatigue, difficulty in concentrating, headache 15.1 73 N
35 f 7 fatigue, difficulty in concentrating, headache 12.4 134 N
36 f 10 fatigue, difficulty in concentrating, headache 12.3 141 N
37 f 8 fatigue, difficulty in concentrating, headache 12.6 144 N
38 f 12 fatigue, difficulty in concentrating, headache 13.4 163 N
Hb = hemoglobin; m = male; f = female; eeg = electroencephalography; emg = electromyelography; veP = visual evoked potential; 
mri = magnetic resonance imaging; NA = not available; N = normal
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headache (n=11); and group 4 of those with convulsion 
(n=4) or other findings (hand tremor, gait ataxia, or 
vision blurring) (n=4).
demographic, clinical, laboratory and imaging 
data are shown in table 1. Thirty-eight patients, 21 
male and 17 female, met the selection criteria. The syn-
cope and dizziness group consisted of four boys and six 
girls, the hypotonia findings group of seven boys and 
two girls, the tingling sensations and paresthesia group 
of four boys and seven girls, and the other findings 
group of six boys and two girls. The mean patient age 
was 8.51 years. A statistically significant difference was 
determined among the groups according to age. The 
age in the hypotonia group (group 2) was significantly 
lower than in the groups with syncope and dizziness 
(group 1), and tingling-paresthesia, fatigue, difficulty 
in concentrating and headache (group 3) (p<0.05).
Patient mean serum B12 level was 137.18 mg/dl. 
B12 distribution according to patient groups is shown 
in table 2. Comparison of pre- and post-treatment 
values within the groups revealed that in the hypotonia 
group, the pre-treatment blood hemoglobin level was 
significantly lower than the post-treatment level 
(p<0.05). Pre-treatment blood hemoglobin levels and 
post-treatment mCv levels in the hypotonia group 
differed from those in other groups (p=0.02 and 
p=0.035, respectively).
One patient from group 4, who presented with in-
fantile spasm, exhibited a hypsarrhythmic pattern on 
eeg, while the three other patients with convulsions 
had normal interictal eeg. The patient with infantile 
spasm also exhibited elevated homocysteine level (17 
µmol/l) (normal range: 5-15 µmol/l) in the urinary 
organic acid profile. All four group 4 patients experi-
enced no recurrence of convulsions after vitamin sup-
plementation. Patients with tingling sensations and 
paresthesia (group 3) underwent emg. One subject 
exhibited sensory neuropathy on emg, while the oth-
ers had normal results. Another nine group 3 patients 
presented with developmental motor delay and hypo-
tonia. four were able to sit without support and five 
were able to support their weight on their feet one 
month after vitamin supplementation. Patients who 
presented with fatigue and concentration difficulty re-
covered, but their headache persisted. All patients with 
syncope underwent cardiologic consultation. Patients 
with dizziness were referred to an otolaryngologist. No 
pathology was determined on otolaryngologic exami-
nation. All patients with syncope underwent pediatric 
cardiologic examination. transthoracic echocardiogra-
phy findings were normal, and no pathological differ-
ence was determined in blood arterial pressure values 
in either standing or supine position. After B12 sup-
plementation (in the form of cyanocobalamin), serum 
vitamin B12 levels normalized and all symptoms ex-
cept for headache resolved within one month.
Discussion
vitamin B12 is essential for development of the 
central nervous system. Nutritional vitamin B12 defi-
ciency in infancy is common in countries with low in-
take of animal products4,6. early treatment prevents 
severe neurological manifestations. measurement of 
vitamin B12 levels can assist in the diagnosis of vita-
min B12 deficiency. Homocysteine and methylmalo-
nic acid levels also are elevated in B12 deficiency. di-
agnosis of vitamin B12 deficiency should not rely on 
an abnormal hemoglobin level, hematocrit level or 
mCv, especially in mild cases10. Although clinical 
neurological manifestations in infants have been de-
scribed very well in several case studies, the underlying 
pathology is not yet fully understood4.
Neurological signs may usually be expected in in-
fants who are exclusively breastfed and who receive 
inadequate amounts of vitamin B12. Hypotonia and 
neurodevelopmental delay are the most commonly re-
ported signs in infants. We observed hypotonia in nine 
cases. Clinical improvement was observed in all pa-
tients after vitamin supplementation.
diagnosis of vitamin B12 deficiency may not cause 
an abnormal blood chart, especially in mild cases10. 
Anemia was not a common condition in our study. A 
significant increase in hemoglobin values was observed 
only in group 2, which consisted of infants with hypo-
tonia (table 2). vitamin B12 deficiency may be a more 
important factor that particularly affects blood chart in 
these groups. We attributed the difference in pre-
treatment hemoglobin levels and post-treatment 
mCv levels in the hypotonia group to the age of pa-
tients in this group, which was composed of very young 
individuals.
Several reports have indicated a correlation be-
tween epilepsy and vitamin B12 deficiency11-13. rat 
studies have suggested that homocysteic acid, a meta-
bolic product of homocysteine, induces convulsions11,12. 
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Table 2. Distribution of age and laboratory values according to patient groups
n mean median min max Sd p
Age (years) group 1 10 12.5 12.5 7 17 2.8
0.001
group 2 9 1.41 1.67 0.75 2 0.56
group 3 11 12.18 12 7 17 4.14
group 4 8 6.48 5 0.83 15 4.69
total 38 8.51 8 0.75 17 5.68
B12 levels before 
treatment
group 1 10 139.4 140.5 109 163 17.12
0.269
group 2 9 140 143 40 188 41.89
group 3 11 123.55 134 73 163 29.32
group 4 8 150 144.5 120 196 23.42
total 38 137.18 139 40 196 29.68
B12 levels after 
treatment
group 1 10 609.4 590.5 430 878 168.06
0.989
group 2 9 722.67 644 345 2000 509.3
group 3 11 727.09 587 339 2000 452.2
group 4 8 658.5 585 300 1043 279.09




group 1 10 12.97 12.95 9.8 15.3 1.52
0.02
group 2 9 11.44 11.3 11 12.5 0.51
group 3 11 13.2 13.4 10.9 15.1 1.25
group 4 8 12.75 12.7 11 15.5 1.42




group 1 10 13.42 13.55 11 14.8 1.12
0.051
group 2 9 12.19 12.3 11 13.1 0.63
group 3 11 13.12 13 11.5 15.3 1.17
group 4 8 13 12.6 12.2 15.4 1.05
total 38 12.95 12.75 11 15.4 1.08
mCv before 
treatment
group 1 10 80.86 81.7 70.4 88.4 5.26
0.355
group 2 9 79.04 79.5 71.5 91.1 5.81
group 3 11 82.65 80.7 78.4 89.8 4.26
group 4 8 79.41 80.4 72.4 85.4 3.99
total 38 80.64 80.55 70.4 91.1 4.91
mCv after 
treatment
group 1 10 80.4 81.35 73.5 83.4 3.51
0.035
group 2 9 77.78 77.8 73.5 81.2 2.46
group 3 11 81.71 80.9 77.8 88.5 3.22
group 4 8 80.4 80.35 77.3 84.7 2.24
total 38 80.16 80.7 73.5 88.5 3.19
group 1 Blood hemoglobin levels before treatment 10 12.97 12.95 9.8 15.3 1.52
0.257
Blood hemoglobin levels after treatment 10 13.42 13.55 11 14.8 1.12
group 2 Blood hemoglobin levels before treatment 9 11.44 11.3 11 12.5 0.51
0.006
Blood hemoglobin levels after treatment 9 12.19 12.3 11 13.1 0.63
group 3 Blood hemoglobin levels before treatment 11 13.2 13.4 10.9 15.1 1.25
0.722
Blood hemoglobin levels after treatment 11 13.12 13 11.5 15.3 1.17
group 4 Blood hemoglobin levels before treatment 11 13.2 13.4 10.9 15.1 1.25
0.722
Blood hemoglobin levels after treatment 11 13.12 13 11.5 15.3 1.17
total Blood hemoglobin levels before treatment 38 12.63 12.45 9.8 15.5 1.38
0.026
Blood hemoglobin levels after treatment 38 12.95 12.75 11 15.4 1.08
mCv = mean corpuscular volume
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There are also reports of patients with infantile spasm 
being successfully treated with B12 supplementa-
tion14,15. in this study, we identified two patients with 
focal convulsion, i.e. one with generalized convulsion 
and another one with infantile spasms. The patient 
with infantile spasm exhibited hypsarrhythmia on 
eeg and was treated successfully with B12 and adre-
nocorticotropic hormone. All patients were subse-
quently seizure-free. The other patient exhibited nor-
mal interictal eeg and mri findings. vitamin B12 
deficiency can also lead to dizziness and syncope. vita-
min B12 is important in the production of adrenaline 
from noradrenaline. it is an essential cofactor involved 
in myelin degradation and in the synthesis of catechol-
amines. Another proposed mechanism is that myelin 
synthesis is disrupted in vitamin B12 deficiency and 
may lead to baroreflex dysfunction, affecting the sym-
pathetic regulation of blood vessels and autonomic 
nervous system16. A cause and effect relationship has 
also been suggested between syncope and postural or-
thostatic tachycardia syndrome in B12 deficiency17. 
vision loss in vitamin B12 deficiency has been regard-
ed as secondary to optic neuropathy18-21. in the present 
study, one patient had vision abnormality and patho-
logical visual evoked potential test results. This patient 
also recovered within a few weeks with B12 supple-
mentation.
Neuropsychiatric abnormalities consist of a wide 
range of symptoms including chronic fatigue syn-
drome, mood disorders, attention deficit, mental status 
and cognitive changes, slow mentation, memory im-
pairment and behavioral abnormalities22,23. Patients 
without macrocytic anemia but with tissue cobalamin 
deficiency can also develop neuropsychiatric abnor-
malities22. Although only one had anemia, eight of our 
patients were affected neuropsychologically. The ab-
sence of quantitative analysis in terms of neuropsycho-
logical tests in patients with fatigue and attention 
deficit was a limitation of this study. However, the fact 
that the symptoms resolved in a few weeks after sup-
plementation of vitamin B12 indicates a cause-effect 
relationship between B12 deficiency and the symp-
toms in question. Patients who presented with fatigue 
and concentration difficulty recovered, but their head-
ache persisted. We conclude that headache was not 
related to vitamin B12 deficiency because the patients 
did not have anemia. Additionally, polyneuropathy is a 
common neurological finding in patients with vitamin 
B12 deficiency. Polyneuropathy due to cobalamin defi-
ciency is often axonal. Neurophysiological and patho-
logical findings indicate axonal degeneration, whether 
or not accompanied by demyelination. in this study, 
three patients were admitted with tingling sensations 
and paresthesia in distal upper extremities. The patho-
genic mechanism of neuropathy in cobalamin defi-
ciency has been attributed to myelin damage involving 
astrocytes and microglia.
Although we made every effort to establish a large 
cohort with a wide variety of symptoms of vitamin 
B12 deficiency, this study still had a number of limita-
tions, as follows: we were unable to screen for homo-
cysteine and methylmalonic acid levels supporting 
B12 deficiency. Only the patient with infantile spasm 
underwent urinary and plasma amino and organic acid 
tests in order to exclude a diagnosis of metabolic dis-
ease; and patient symptoms and signs could not be 
evaluated with neuropsychological investigation.
in conclusion, vitamin B12 deficiency should be 
considered in patients with congenital hypotonia, syn-
cope, gait ataxia, convulsions, vision loss or vision blur-
ring, neuropathy, dizziness or tremor, even in the ab-
sence of anemia. Since nervous system symptoms can 
precede anemia by months, patients with neurological 
symptoms should be carefully evaluated in terms of vi-
tamin B12 deficiency with or without associated ane-
mia. Since immediate and accurate treatment prevents 
progression of the disease, a cautious and aware ap-
proach is essential. We believe that this study indicates 
the importance of screening for vitamin B12 in pa-
tients from low-income and populous communities 
and with the symptoms described.
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Sažetak
NeurOlOŠKi SimPtOmi NedOStAtKA vitAmiNA B12:  
ANAliZA PediJAtriJSKiH BOleSNiKA
H. M. Serin i E. Acar Arslan
vitamin B12 jedan je od ključnih vitamina koji utječe na razne sustave u organizmu uključujući središnji živčani sustav. 
vitamin B12 ima važnu ulogu u metabolizmu živčanog sustava, iako njegova uloga u patološkim stanjima nije u potpunosti 
razjašnjena. Namjera ovoga istraživanja bila je naglasiti važnost rane dijagnoze nedostatka vitamina B12 u svjetlu karakteri-
stika bolesnika uključenih u istraživanje. Ovo retrospektivno kliničko istraživanje uključilo je 38 djece s neurološkim simp-
tomima nedostatka vitamina B12. retrospektivno su analizirani podaci za 38 djece upućene u ambulantu za dječju neurolo-
giju jedne sveučilišne bolnice zbog neuroloških simptoma nedostatka vitamina B12 između veljače 2012. i prosinca 2013. 
godine. uključeni su bolesnici u dobi od 0 do 18 godina sa sljedećim simptomima uzrokovanim nedostatkom vitamina B12: 
sinkopa, vrtoglavica, konvulzije, hipotonija, zastoj u razvoju, tremor, ataksija, trnci i parestezije, zamagljen vid, umor i otežana 
koncentracija. u bolesnika su zabilježeni sljedeći neurološki nalazi: sinkopa (n=6), vrtoglavica (n=4), hipotonija (n=9), nemo-
gućnost da sjedi ili hoda bez potpore, ili ataksija u hodu (n=2), konvulzije (n=4), tremor ruku (n=1), trnci i parestezija (n=3), 
zamagljen vid (n=1), umor i otežana koncentracija (n=8). Svi bolesnici s neurološkim simptomima nedostatka vitamina B12 
oporavili su se kroz jedan mjesec nakon nadomještanja vitamina B12. u zaključku, kliničke značajke nedostatka vitamina 
B12 široke su i nespecifične te ne moraju biti udružene s anemijom i povećanim srednjim korpuskularnim volumenom. Kako 
se razne kliničke značajke mogu zapaziti bez anemije, svijest o ovom nedostatku i pažljiv pristup bitni su kako bi se izbjegla 
teška klinička bolest, poglavito u djece iz manje razvijenih zemalja.
Ključne riječi: Središnji živčani sustav; Neurološke manifestacije; Vitamin B12, deficijencija; Dojenče; Dijete; Retrospektivne 
studije
